Veronique De Brabandere

Ablynx (Belgium) — Belgium

Engineering · Physical Sciences

6h-index793citations21works2.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Innovative Microfluidic and Catalytic Techniques Innovation(7), RNA Interference and Gene Delivery(3), Monoclonal and Polyclonal Antibodies Research(3), CAR-T cell therapy research(3), Advanced biosensing and bioanalysis techniques(2)

Publications21 total

Whole-Body Dynamic PET Imaging of Half-Life Extended Variable Domains of Heavy Chain-Only Antibodies: Beyond Blood Pharmacokinetics
Molecular Pharmaceutics·2026
Affinity Tuning of Albumin-Binding VHH Constructs to Modulate Blood Circulation for Optimized Radiopharmaceutical Performance
Nuclear Medicine and Biology·2025Open Access
Transdermal Administration of Nanobody Molecules using Hydrogel‐Forming Microarray Patch Technology: A Unique Delivery Approach
Macromolecular Materials and Engineering·2024· 5 citedOpen Access
Reproducibility Study on a PBPK Model of FcRn-Mediated Recycling for Large Molecules
Physiome·2024Open Access
Reproducibility Study on a PBPK Model of FcRn-Mediated Recycling for Large Molecules
Physiome·2024Open Access
Reproducibility Study on a PBPK Model of FcRn-Mediated Recycling for Large Molecules
Physiome·2024Open Access
Reproducibility Study on a PBPK Model of FcRn-Mediated Recycling for Large Molecules
Physiome·2024Open Access
Reproducibility Study on a PBPK Model of FcRn-Mediated Recycling for Large Molecules
Physiome·2024Open Access
Reproducibility Study on a PBPK Model of FcRn-Mediated Recycling for Large Molecules
Physiome·2024Open Access
Reproducibility Study on a PBPK Model of FcRn-Mediated Recycling for Large Molecules
Physiome·2024Open Access
Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile
Blood Advances·2024· 19 citedOpen Access
Dual-Targeting CD33/CD123 NANOBODY ® T Cell Engager Targeting Leukemia Blasts and Stem/Progenitor Cells in Relapsed AML
Blood·2023· 1 cited
1198 A dual targeting CD33/CD123 NANOBODY® T-cell engager with potent anti-AML activity and a manageable safety profile
Regular and Young Investigator Award Abstracts·2022Open Access
Nanobodies® † †Nanobody is a registered trademark of Ablynx NV. as inhaled biotherapeutics for lung diseases
Pharmacology & Therapeutics·2016· 176 cited
Pichia pastoris MutS strains are prone to misincorporation of O-methyl-l-homoserine at methionine residues when methanol is used as the sole carbon source
Microbial Cell Factories·2016· 26 citedOpen Access
Establishment of a method for a juvenile inhalation study in very young rats
Toxicology Letters·2015
NON-CLINICAL SAFETY ASSESSMENT OF ALX-0171, a NANOBODY® INTENDED FOR CLINICAL ADMINISTRATION VIA NEBULISATION
2013
118 GENERATION OF RECOMBINANT HUMAN ANTI-E1 MONOCLONAL ANTIBODIES THAT EFFECTIVELY NEUTRALIZE HCV IN VITRO
Journal of Hepatology·2008Open Access
Rational Design of a Multiepitope Vaccine Encoding T-Lymphocyte Epitopes for Treatment of Chronic Hepatitis B Virus Infections
Journal of Virology·2007· 107 citedOpen Access
Symmetrical dimethylation of arginine residues in spliceosomal Sm protein B/B′ and the Sm-like protein LSm4, and their interaction with the SMN protein
RNA·2001· 366 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Tom Van Bogaert(9), Soroush Safaei(7), Wilhelmus E. A. de Witte(7), Lindsay B. Avery(7), Maria Laura Sargentini‐Maier(7), Koen Allosery(4), Lydie Meheus(3), Annelies Roobrouck(3), Geert Deschamps(3), Hélène Bonnevaux(3), S. Guérif(3), Angéla Virone-Oddos(3), Marielle Chiron(3), Mélissa Dullaers(3), Peter Casteels(3), Erik Depla(2), Zhihong Zeng(2), Céline Amara(2), Eline Dejonckheere(2), Marina Konopleva(2)